Advertisement

Reactions Weekly

, Volume 1722, Issue 1, pp 204–205 | Cite as

Ledipasvir/sofosbuvir/sofosbuvir

Drug resistance leading to virological failure: 11 case reports
Case report
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

In a comprehensive analysis consisting of 12012 patients, 11 patients were described, who developed sofosbuvir or sofosbuvir/ledipasvir resistance leading to virological failure following treatment for hepatitis C virus (HCV) infection [age and sex not stated for all; routes and dosages not stated].

Patient 1: A 52-year-old woman developed sofosbuvir resistance leading to virologic failure following treatment for HCV infection. The woman, who had HCV genotype 2b infection, received treatment with sofosbuvir for 12 weeks. At 4 weeks post-treatment, her HCV relapsed. S282T was detected at a frequency of >99%. The frequency of S282T rapidly decreased to 27.6% at week 8 and <1% at week 12 post-treatment. She was retreated with sofosbuvir and ribavirin for 12 weeks. Twelve weeks...

Reference

  1. Gane EJ, et al. The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatment. Hepatology Communications 1: 538-549, No. 6, Aug 2017. Available from: URL: http://doi.org/10.1002/hep4.1060 - New Zealand

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations